KEYMED BIO-B Surges Over 6% Pre-Market as H1 Drug Sales Climb 132%

Deep News

Aug 20

Shares of KEYMED BIO-B (02162) climbed more than 7% during intraday trading, with the stock last up 6.42% at HK$82, on a turnover of HK$103 million.

The company announced on August 19, 2026 that its board had resolved to propose an issuance of ordinary shares on the Shanghai Stock Exchange's Science and Technology Innovation Board (STAR Market), to be traded in Renminbi. The proposed issuance is subject to, and dependent upon, market conditions, further board approval, shareholder approval at a general meeting, and the receipt of necessary regulatory approvals.

Previously, KEYMED BIO-B issued a positive profit alert, expecting to record a profit of no less than RMB 1.2 billion for the first half of 2026. Its innovative product, Kangyueda, continued to expand patient coverage thanks to its strong clinical value, generating sales revenue of RMB 390 million in H1 2026, up 132% year-on-year, providing a sustained revenue stream for the company.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.etasphere.com/news/1136749730"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1136749730\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1136749730?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-08-20 11:50","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1136749730","market":"nz","top_or_hot":-1,"title":"KEYMED BIO-B Surges Over 6% Pre-Market as H1 Drug Sales Climb 132%","media":"Deep News","content":"<p>Shares of <b>KEYMED BIO-B</b> (02162) climbed more than 7% during intraday trading, with the stock last up 6.42% at HK$82, on a turnover of HK$103 million.<br><br>The company announced on August 19, 2026 that its board had resolved to propose an issuance of ordinary shares on the Shanghai Stock Exchange's Science and Technology Innovation Board (STAR Market), to be traded in Renminbi. The proposed issuance is subject to, and dependent upon, market conditions, further board approval, shareholder approval at a general meeting, and the receipt of necessary regulatory approvals.<br><br>Previously, <b>KEYMED BIO-B</b> issued a positive profit alert, expecting to record a profit of no less than RMB 1.2 billion for the first half of 2026. Its innovative product, Kangyueda, continued to expand patient coverage thanks to its strong clinical value, generating sales revenue of RMB 390 million in H1 2026, up 132% year-on-year, providing a sustained revenue stream for the company.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>KEYMED BIO-B Surges Over 6% Pre-Market as H1 Drug Sales Climb 132%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nKEYMED BIO-B Surges Over 6% Pre-Market as H1 Drug Sales Climb 132%\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1039043262\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/8296859682db4b478146245e72de1922);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Deep News </p>\n<p class=\"h-time\">2026-08-20 11:50</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Shares of <b>KEYMED BIO-B</b> (02162) climbed more than 7% during intraday trading, with the stock last up 6.42% at HK$82, on a turnover of HK$103 million.<br><br>The company announced on August 19, 2026 that its board had resolved to propose an issuance of ordinary shares on the Shanghai Stock Exchange's Science and Technology Innovation Board (STAR Market), to be traded in Renminbi. The proposed issuance is subject to, and dependent upon, market conditions, further board approval, shareholder approval at a general meeting, and the receipt of necessary regulatory approvals.<br><br>Previously, <b>KEYMED BIO-B</b> issued a positive profit alert, expecting to record a profit of no less than RMB 1.2 billion for the first half of 2026. Its innovative product, Kangyueda, continued to expand patient coverage thanks to its strong clinical value, generating sales revenue of RMB 390 million in H1 2026, up 132% year-on-year, providing a sustained revenue stream for the company.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1583","symbol_name":"高瓴概念","start_time":0,"source_url":"","article_id":"1136749730","we_media_id":"1039043262","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1136749730","pubTimestamp":1787197821,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Deep News","introduction":"Global Stock Market Deep Analysis","home_visible":1,"id":"1039043262","head_image":"https://community-static.tradeup.com/news/8296859682db4b478146245e72de1922"},"summary":"Shares of KEYMED BIO-B (02162) climbed more than 7% during intraday trading, with the stock last up 6.42% at HK$82, on a turnover of HK$103 million.The company announced on August 19, 2026 that its...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK1583":"高瓴概念","BK1161":"生物科技","BK1587":"次新股","BK1574":"生物医药B类股","02162":"康诺亚-B"},"translate_title":"KEYMED BIO-B 上市前股价飙升超过 6%，上半年药品销售额攀升 132%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02162":1},"content_text":"Shares of KEYMED BIO-B (02162) climbed more than 7% during intraday trading, with the stock last up 6.42% at HK$82, on a turnover of HK$103 million.The company announced on August 19, 2026 that its board had resolved to propose an issuance of ordinary shares on the Shanghai Stock Exchange's Science and Technology Innovation Board (STAR Market), to be traded in Renminbi. The proposed issuance is subject to, and dependent upon, market conditions, further board approval, shareholder approval at a general meeting, and the receipt of necessary regulatory approvals.Previously, KEYMED BIO-B issued a positive profit alert, expecting to record a profit of no less than RMB 1.2 billion for the first half of 2026. Its innovative product, Kangyueda, continued to expand patient coverage thanks to its strong clinical value, generating sales revenue of RMB 390 million in H1 2026, up 132% year-on-year, providing a sustained revenue stream for the company.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"2","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}